Investor Presentaiton

Key Business Performance YuflymaⓇ ✓ Yuflyma®, a biosimilar with HumiraⓇ's most similar specification, will be launched in the US in Jul.2023 ✓ Initiated a global Phase 3 clinical trial to demonstrate the interchangeability of YuflymaⓇ with HumiraⓇ Global market size of Adalimumab Specifications by product 100% 3% 5%0 Product Name High concentration Interchangeability 5% 15% HumiraⓇ O 75% 16% YuflymaⓇ O Global 13% 80% Adalimumab 50% 19% A X Market Size $34.6bn 7% B Δ 25% 42% 0% ■ HumiraⓇ US ■ Europe ■ROW ImraldiⓇ ■ Hulio® ■ AmgevitaⓇ HyrimozⓇ Idacio® Note: The market size is as of 2021 Source: IQVIA C о D X Note: indicates clinical trial to support interchangeability ongoing Investor Relations 2022 13

View entire presentation